Traditional clinical trials are built on a simple, slow logic: give half the participants a vaccine, the other half a placebo, and wait for enough people to get sick to see if the vaccine worked. But as pathogens like SARS-CoV-2 mutate rapidly and ethical standards for HIV prevention rise, this "wait and see" approach has become a bottleneck.
Researchers are moving toward a faster framework: immunobridging. Instead of waiting for clinical endpoints (infections), they measure correlates of protection (CoP)—biological markers, like antibody levels in the blood, that reliably predict whether a person is protected.
The Problem with the Placebo Standard
In the early days of a pandemic, placebo-controlled trials are straightforward. However, as Peter B. Gilbert notes, once effective preventions like PrEP for HIV or existing vaccines for COVID-19 become standard, it becomes ethically difficult and statistically complex to deny participants a known defense Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs.
Furthermore, viruses evolve faster than a six-month Phase 3 trial can conclude. If a new variant emerges, we need to know if a booster works in weeks, not years. This necessitates a shift from "clinical endpoint trials" to "immuno-bridging studies," where a vaccine's success is judged by its ability to trigger a specific, validated immune response.
Identifying the Correlates of Protection
To bypass the Phase 3 trial, we must first prove that a specific biomarker (like a neutralizing antibody titer) actually causes protection. This isn't just about correlation; it's about establishing a "surrogate endpoint."
In the context of COVID-19, researchers like David Benkeser and Holly Janes analyzed the AstraZeneca and Moderna trials to find these benchmarks. They found that anti-spike IgG and neutralizing antibody (nAb) titers are remarkably consistent predictors of risk Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine.
The intuition is that if we can map a "protection curve"—showing that, for example, a specific concentration of antibodies corresponds to 90% efficacy—we can evaluate any new vaccine iteration simply by checking if it hits that concentration Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infection.
The Logic of Immunobridging
Immunobridging acts as a statistical "shortcut." If Vaccine A was proven effective in a massive trial and produced a certain level of antibodies, and a new Vaccine B (or a booster for a new variant) produces the same level of antibodies in a small group of people, we can "bridge" the efficacy of Vaccine A to Vaccine B.
This framework has been successfully applied across different vaccine technologies. Youyi Fong and colleagues demonstrated that these immune markers remain valid even for different platforms, such as the protein-based Novavax vaccine Immune Correlates Analysis of the PREVENT-19 COVID-19 Vaccine Efficacy Clinical Trial and the viral-vector Johnson & Johnson vaccine Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial.
Moving from Association to Causation
A major hurdle in this field is ensuring that the biomarker is a true surrogate, not just a bystander. Peter B. Gilbert, Michael G. Hudgens, and Julian Wolfson argue for the use of Principal Stratification, a causal inference framework. This method helps researchers determine if the vaccine works because it raised the biomarker, or if the biomarker is just a sign of a healthy immune system Commentary on "Principal Stratification -- a Goal or a Tool?" by Judea Pearl.
By standardizing these models, a government-led effort coordinated by Richard A. Koup and others has sought to harmonize assays across the industry. The goal is to reduce vaccine development timelines by more than half, allowing for rapid regulatory approval of updates through small immunogenicity trials rather than massive observational studies A government-led effort to identify correlates of protection for COVID-19 vaccines.
Beyond Vaccines: Monoclonal Antibodies and Rare Diseases
The immunobridging concept is expanding beyond traditional vaccines. For instance, Rhiannon Edge and colleagues developed a "Threshold of Protection" model for monoclonal antibodies. By integrating drug concentration and in vitro potency against new variants, they can predict clinical efficacy without needing a new trial for every emerging strain A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19.
Even in neurodegenerative diseases like Huntington’s, researchers are looking for similar shortcuts. Filipe B. Rodrigues and colleagues have shown that biofluid biomarkers like neurofilament light (NfL) can detect treatment effects much more efficiently than traditional clinical scales, potentially allowing for smaller and shorter trials Longitudinal dynamics of mutant huntingtin and neurofilament light in Huntington’s disease: the prospective HD-CSF study.